Activity of afatinib in heavily pretreated patients (pts) with HER2 mutation-positive (HER2m+) advanced non-small cell lung cancer (NSCLC): findings from a global named patient use (NPU) program

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Background: Approximately 1–4% of lung adenocarcinomas harbour a HER2 mutation. No targeted treatment is approved yet for this NSCLC pt subgroup. Initial results for the treatment of HER2m+ NSCLC with the irreversible ErbB family blocker, afatinib, have been encouraging, with some pts showing notable responses or promising disease control. Pts with HER2m+ NSCLC were included in a global NPU program for afatinib, which was initiated in 2010, and their treatment outcomes are presented here.